Financials Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/05/2024 BST 5-day change 1st Jan Change
5.11 USD -3.04% Intraday chart for Vanda Pharmaceuticals Inc. -0.39% +21.09%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 875.3 718.6 874.1 418.2 242.8 297.4 - -
Enterprise Value (EV) 1 875.3 718.6 874.1 418.2 242.8 108.5 362.5 660.5
P/E ratio 7.78 x 31.3 x 27.1 x 67.2 x 106 x -85.2 x -15.5 x 39.3 x
Yield - - - - - - - -
Capitalization / Revenue 3.85 x 2.9 x 3.25 x 1.64 x 1.26 x 1.53 x 1.28 x 1.96 x
EV / Revenue 3.85 x 2.9 x 3.25 x 1.64 x 1.26 x 0.56 x 1.56 x 4.34 x
EV / EBITDA 22.4 x - 19.4 x - - -5.37 x -9.72 x 55.5 x
EV / FCF - - - - - 0.57 x 1.43 x 2.22 x
FCF Yield - - - - - 175% 70.1% 45.1%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 53,337 54,692 55,712 56,590 57,532 58,198 - -
Reference price 2 16.41 13.14 15.69 7.390 4.220 5.110 5.110 5.110
Announcement Date 25/02/20 10/02/21 23/02/22 08/02/23 07/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 227.2 248.2 268.7 254.4 192.6 194.5 232.4 152.1
EBITDA 1 39.16 - 45.01 - - -20.2 -37.3 11.9
EBIT 1 22.81 27.24 42.16 6.329 -13.95 -21.4 -38.5 10.7
Operating Margin 10.04% 10.98% 15.69% 2.49% -7.24% -11% -16.57% 7.03%
Earnings before Tax (EBT) 1 29.03 31.66 42.36 11.3 6.339 -1.9 -19.5 10.7
Net income 1 115.6 23.34 33.15 6.275 2.509 -3.6 -19.5 8.5
Net margin 50.86% 9.4% 12.34% 2.47% 1.3% -1.85% -8.39% 5.59%
EPS 2 2.110 0.4200 0.5800 0.1100 0.0400 -0.0600 -0.3300 0.1300
Free Cash Flow 1 - - - - - 190 254 298
FCF margin - - - - - 97.69% 109.29% 195.92%
FCF Conversion (EBITDA) - - - - - - - 2,504.2%
FCF Conversion (Net income) - - - - - - - 3,505.88%
Dividend per Share - - - - - - - -
Announcement Date 25/02/20 10/02/21 23/02/22 08/02/23 07/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4
Net sales 1 68.02 60.19 64.39 65.32 64.48 46.06 38.82 45.27
EBITDA 9.342 - - - - - - -
EBIT 1 8.636 -7.669 3.461 3.908 6.629 -2.867 -5.995 -7.094
Operating Margin 12.7% -12.74% 5.38% 5.98% 10.28% -6.23% -15.45% -15.67%
Earnings before Tax (EBT) 1 8.61 -7.564 3.79 5.461 9.613 2.592 -0.12 -1.661
Net income 1 7.078 -6.43 2.574 3.27 6.861 1.52 0.137 -2.4
Net margin 10.41% -10.68% 4% 5.01% 10.64% 3.3% 0.35% -5.3%
EPS 2 0.1200 -0.1100 0.0500 0.0600 0.1200 0.0300 - -0.0400
Dividend per Share - - - - - - - -
Announcement Date 23/02/22 05/05/22 03/08/22 02/11/22 08/02/23 27/07/23 08/11/23 07/02/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - 65.1 363
Net Cash position 1 - - - - - 189 - -
Leverage (Debt/EBITDA) - - - - - - -1.745 x 30.51 x
Free Cash Flow 1 - - - - - 190 254 298
ROE (net income / shareholders' equity) - - 6.92% - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - 1.130 - - - - -
Capex 1 - - - - - 1.3 1.4 1.4
Capex / Sales - - - - - 0.67% 0.6% 0.92%
Announcement Date 25/02/20 10/02/21 23/02/22 08/02/23 07/02/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.11 USD
Average target price
5.21 USD
Spread / Average Target
+1.96%
Consensus
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. Financials Vanda Pharmaceuticals Inc.